Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2016 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
ARVINAS INC | 14 | Q3 2023 | 4.9% |
ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
NATERA INC | 13 | Q3 2023 | 1.9% |
ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
ABBVIE INC | 12 | Q2 2023 | 9.7% |
HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-13 |
SC 13G | 2024-04-09 |
SC 13G | 2024-03-27 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.